Suppr超能文献

一项前瞻性研究,比较人血白蛋白与在肝硬化合并顽固性腹水患者进行完全腹腔穿刺放液后回输超滤后的腹水。

Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites.

作者信息

Zaak D, Paquet K J, Kuhn R

机构信息

Heinz-Kalk-Hospital, Dep. of Surgery and Medicine, D-97688 Bad Kissingen, Germany.

出版信息

Z Gastroenterol. 2001 Jan;39(1):5-10. doi: 10.1055/s-2001-10707.

Abstract

Although, total paracentesis associated with human albumin substitution has shown to be a rapid, effective and safe treatment of diuretic refractory ascites in advanced liver cirrhosis, it implies high costs and has a limited availability. Therefore an alternative procedure the reinfusion of concentrated ascites has gained popularity in recent years (Smart et al. 1990; Grazioto et al. 1997). It was the aim of the study to compare human albumin substitution vs. reinfusion of ascitic-ultrafiltrate after total paracentesis. 35 patients with cirrhosis and tense ascites received total paracentesis associated with either human albumin (5-8 g/l ascites) (= group A) or reinfusion of an ascitic-ultrafiltrate fluid by means of hemofiltration technique (= group B). The mean volume of ascites removed was 9.41 (2.1-20.0) in group A and 11.41 (6.5-21.0) in group B. No significant differences in serum electrolytes, liver and renal function, coagulation profiles and hormones of the renin-angiotensin-aldosterone system were observed during hospitalization. In both groups sodium excretion increased significantly. 43% of the patients in group B developed pyrexia and chill after reinfusion of the ascitic-ultrafiltrate fluid. In one patient an anaphylactic bronchospasm occurred requiring IUC-treatment. The treatment cost in case of human albumin were 326.-DM vs. 290.-DM for each patient treated with ascitic-ultrafiltrate fluid reinfusion. The probabilities of hospital readmission and survival were similar in both groups during follow-up. The results indicate that i.v. infusion of ascitic-ultrafiltrate fluid is as effective as total paracentesis and albumin infusion in case of diuretic refractory ascites. However, according to the costs of instruments and staff and due to the significant allergic reactions caused by ascitic fluid it cannot be considered as a real alternative to albumin substitution.

摘要

尽管大量放腹水联合人血白蛋白替代治疗已被证明是晚期肝硬化患者利尿剂抵抗性腹水的一种快速、有效且安全的治疗方法,但该方法成本高昂且供应有限。因此,近年来一种替代方法——浓缩腹水回输受到了广泛关注(Smart等人,1990年;Grazioto等人,1997年)。本研究旨在比较大量放腹水后人血白蛋白替代治疗与腹水超滤回输的效果。35例肝硬化伴张力性腹水患者接受了大量放腹水治疗,其中一组(A组)在放腹水后给予人血白蛋白(每升腹水5 - 8克),另一组(B组)通过血液滤过技术回输腹水超滤液。A组平均放腹水量为9.41(2.1 - 20.0)升,B组为11.41(6.5 - 21.0)升。住院期间,两组患者的血清电解质、肝肾功能、凝血指标以及肾素 - 血管紧张素 - 醛固酮系统激素水平均无显著差异。两组患者的钠排泄量均显著增加。B组43%的患者在回输腹水超滤液后出现发热和寒战。1例患者发生过敏性支气管痉挛,需要重症监护治疗。使用人血白蛋白治疗的每位患者费用为326德国马克,而使用腹水超滤液回输治疗的每位患者费用为290德国马克。随访期间,两组患者再次入院的概率和生存率相似。结果表明,对于利尿剂抵抗性腹水,静脉输注腹水超滤液与大量放腹水及白蛋白输注效果相当。然而,考虑到仪器和人员成本,以及腹水引起的显著过敏反应,腹水超滤液回输不能被视为白蛋白替代治疗的真正替代方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验